Intracoronary glycoprotein IIb/IIIa inhibitors: From questioning the logic to weighing the data

JACC: Cardiovascular Interventions

Volumn 3, Issue 9, 2010, Pages 935-936

  Berger, Peter B ^a   Best, Patricia J M ^b  

^a GEISINGER MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

glycoprotein IIb IIIa inhibitors; intracoronary; intravenous; major adverse cardiac events; myocardial infarction; percutaneous coronary intervention

Indexed keywords

FIBRINOGEN RECEPTOR; GLYCOPROTEIN 2B 3A INHIBITOR; UNCLASSIFIED DRUG;

DRUG DELIVERY SYSTEM; HEART INFARCTION; HUMAN; INTRACORONARY INFUSION; NOTE; PRIORITY JOURNAL; ST SEGMENT; THROMBOCYTE; THROMBOSIS;

EID: 77956630961     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.08.008     Document Type: Editorial

References (22)

1. J.E. Tcheng, S.G. Ellis, and B.S. George Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty Circulation 90 1994 1757 1764
2. P.B. Berger The glycoprotein IIb/IIIa inhibitor wars: an update J Am Coll Cardiol 56 2010 476 478
3. S. Thuraisingham, and K.H. Tan Dissolution of thrombus formed during direct coronary angioplasty with a single 10 mg intracoronary bolus dose of abciximab Int J Clin Pract 53 1999 604 607
4. A.L. Bartorelli, D. Trabattoni, S. Galli, L. Grancini, S. Cozzi, and P. Ravagnani Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA Catheter Cardiovasc Interv 48 1999 211 213
5. S.S. Patel, H. Rana, and D.A. Mascarenhas Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience J Cardiovasc Pharmacol Ther 13 2008 89 93
6. J. Wohrle, O.C. Grebe, and T. Nusser Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty Circulation 107 2003 1840 1843
7. A.K. Kakkar, A. Moustapha, and H.G. Hanley Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting Catheter Cardiovasc Interv 61 2004 31 34
8. H. Thiele, K. Schindler, and J. Friedenberger Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention Circulation 118 2008 49 57
9. J.G. Galache Osuna, J. Sanchez-Rubio, I. Calvo, J.A. Diarte, A. Lukic, and L.J. Placer Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial Rev Esp Cardiol 59 2006 567 574
10. D.S. Pinto, A.J. Kirtane, and N.A. Ruocco Administration of intracoronary eptifibatide during ST-elevation myocardial inf Am J Cardiol 96 2005 1494 1497
11. A.J. Deibele, A.J. Kirtane, and D.S. Pinto Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina J Thromb Thrombolysis 22 2006 47 50
12. W. Hassan, H. Al-Sergani, and J. Al Buraiki Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study Am Heart J 154 2007 345 351
13. T.G. Wu, Q. Zhao, and W.G. Huang Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome Circ J 72 2008 1605 1609
14. X.C. Yang, D.P. Zhang, and L.F. Wang Effects of intracoronary or intravenous tirofiban administration in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention Zhonghua Xin Xue Guan Bing Za Zhi 35 2007 517 522
15. S. Goto, N. Tamura, and H. Ishida Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions J Am Coll Cardiol 44 2004 316 323
16. M. Moser, U. Bertram, K. Peter, C. Bode, and J. Ruef Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates J Cardiovasc Pharmacol Ther 41 2003 586 592
17. A.J. Deibele, L.K. Jennings, J.E. Tcheng, C. Neva, A.D. Earhart, and C.M. Gibson Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) trial Circulation 121 2010 784 791
18. D.B. Fram, T. Aretz, and M.A. Azrin Localized intramural drug delivery during balloon angioplasty using hydrogel-coated balloons and pressure-augmented diffusion J Am Coll Cardiol 23 1994 1570 1577
19. M.H. Yoon, S.J. Tahk, and H.M. Yang Comparison of the intracoronary continuous infusion method using a microcatheter and the intravenous continuous adenosine infusion method for inducing maximal hyperemia for fractional flow reserve measurement Am Heart J 157 2009 1050 1056
20. V. Kunadian, C. Zorkun, and S.P. Williams Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction J Thromb Thrombolysis 26 2008 234 242
21. F. Bellandi, M. Maioli, M. Gallopin, A. Toso, and R.P. Dabizzi Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention Catheter Cardiovasc Interv 62 2004 186 192
22. F. Prati, D. Capodanno, and T. Pawlowski Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes J Am Coll Cardiol Intv 3 2010 928 934